Zevra Therapeutics, Inc. $ZVRA Stock Holdings Lowered by Simplify Asset Management Inc.

Simplify Asset Management Inc. lessened its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 71.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 42,365 shares of the company’s stock after selling 104,635 shares during the period. Simplify Asset Management Inc.’s holdings in Zevra Therapeutics were worth $380,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its stake in Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after purchasing an additional 4,475 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares during the period. Creative Planning acquired a new stake in shares of Zevra Therapeutics in the second quarter valued at approximately $92,000. Quarry LP bought a new stake in shares of Zevra Therapeutics during the third quarter valued at approximately $103,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Zevra Therapeutics during the second quarter valued at approximately $99,000. 35.03% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. BTIG Research began coverage on Zevra Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $23.00 price objective for the company. Weiss Ratings downgraded Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, April 11th. Finally, Guggenheim raised their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.33.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock opened at $10.03 on Monday. Zevra Therapeutics, Inc. has a 12-month low of $7.16 and a 12-month high of $13.16. The stock has a market capitalization of $592.97 million, a PE ratio of 5.04 and a beta of 0.88. The firm has a 50 day simple moving average of $10.04 and a 200-day simple moving average of $9.26.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.06 by $0.12. The firm had revenue of $36.22 million for the quarter, compared to analysts’ expectations of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. On average, analysts forecast that Zevra Therapeutics, Inc. will post 0.56 earnings per share for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.